Literature DB >> 32222729

Investigating the theragnostic potential of 131I-caerin peptide in thyroid cancer.

Ying Ying Zhou1, Pei Pei Zhang, Ruo Ting Lin, Tong Sheng Chen, Xiong Ying Liu, Wen Juan Liu, Yong Nan Liang, Shu Chen, Xuan Pan, Guo Ying Ni, Tian Fang Wang, Xiao Song Liu, Jian Wei Yuan.   

Abstract

OBJECTIVE: Caerin is a new peptide with tumour toxicity and its uptake by tumour cells is independent of the sodium iodide symporter (NIS). Thyroid cancer is the most common cancers of endocrine malignancy. Radioiodine (131I)-refractory thyroid cancer is the most lethal subtype of the thyroid cancers and remains a clinical challenge. In the current study, we investigated the 131I radiolabeling efficiency of Caerin and the effects of Caerin, 131I-Caerin and free 131I on differentiated and undifferentiated human thyroid cancer cell lines (B-CPAP and CAL-62) in vitro.
MATERIALS AND METHODS: Cell Counting Kit-8 was used to assess the cytotoxic effect of Caerin, 131I-Caerin and free 131I on B-CPAP and CAL-62 cells. Laser scanning confocal microscope was exploited to evaluate the uptake and internalization of Caerin by thyroid cancer cells. The Chloramine-T method was used to label the peptide with 131I. And the stability and water partition coefficient (Log P) of 131I-Caerin were studied.
RESULTS: Our results demonstrated that Caerin and 131I-Caerin could be accumulated by B-CPAP and CAL-62 cells, resulting in killing of the thyroid cancer cells in vitro. The efficacy of 131I-Caerin is much higher than 131I, especially to undifferentiated CAL-62 cells. The results prove the feasibility of radioiodination of the 131I-Caerin via the Chloramine-T method. Moreover, the result indicate the hydrophobic 131I-Caerin was stable in 72 hours.
CONCLUSION: Iodine-131-Caerin can inhibit the cell viability of thyroid cancer and hold certain promise as a theragnostic tool for human thyroid cancers.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32222729     DOI: 10.1967/s002449912003

Source DB:  PubMed          Journal:  Hell J Nucl Med        ISSN: 1790-5427            Impact factor:   1.102


  3 in total

1.  Targeted radioimmunotherapy with the iodine-131-labeled caerin 1.1 peptide for human anaplastic thyroid cancer in nude mice.

Authors:  Ruoting Lin; Bowei Ma; Na Liu; Lu Zhang; Tiantian He; Xiongying Liu; Tongsheng Chen; Wenjuan Liu; Yongnan Liang; Tianfang Wang; Guoying Ni; Xiaosong Liu; Ning Yang; Jinhe Zhang; Jianwei Yuan
Journal:  Ann Nucl Med       Date:  2021-05-04       Impact factor: 2.668

2.  Preclinical Pharmacokinetics, Biodistribution, and Acute Toxicity Evaluation of Caerin 1.9 Peptide in Sprague Dawley Rats.

Authors:  Xiaodan Yang; Junjie Li; Shu Chen; Liyin Xiao; Dongmin Cao; Xiaolian Wu; Hejie Li; Guoying Ni; Tianfang Wang; Guoqiang Chen; Xiaosong Liu
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-02       Impact factor: 2.650

3.  131I-Caerin 1.1 and 131I-Caerin 1.9 for the treatment of non-small-cell lung cancer.

Authors:  Na Liu; Tiantian He; Zewei Xiao; Juan Du; Keke Zhu; Xiongying Liu; Tongsheng Chen; Wenjuan Liu; Guoying Ni; Xiaosong Liu; Tianfang Wang; Jiangtao Quan; Jinhe Zhang; Peipei Zhang; Jianwei Yuan
Journal:  Front Oncol       Date:  2022-08-15       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.